tradingkey.logo

SI-BONE Inc

SIBN
15.770USD
+0.580+3.82%
Close 11/07, 16:00ETQuotes delayed by 15 min
678.33MMarket Cap
LossP/E TTM

SI-BONE Inc

15.770
+0.580+3.82%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of SI-BONE Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SI-BONE Inc's Score

Industry at a Glance

Industry Ranking
33 / 209
Overall Ranking
93 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 9 analysts
Buy
Current Rating
24.778
Target Price
+57.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

SI-BONE Inc Highlights

StrengthsRisks
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 57.11% year-on-year.
Undervalued
The company’s latest PE is -28.10, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.43M shares, decreasing 9.37% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 150.02K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.71, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 48.63M, representing a year-over-year increase of 21.67%, while its net profit experienced a year-over-year increase of 31.18%.

Score

Industry at a Glance

Previous score
7.71
Change
0

Financials

7.80

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.48

Operational Efficiency

10.00

Growth Potential

7.01

Shareholder Returns

7.23

SI-BONE Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.11, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -28.10, which is -74.74% below the recent high of -7.10 and -19.34% above the recent low of -33.53.

Score

Industry at a Glance

Previous score
7.11
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 33/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.44, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for SI-BONE Inc is 25.00, with a high of 32.00 and a low of 20.00.

Score

Industry at a Glance

Previous score
8.44
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts
Buy
Current Rating
24.778
Target Price
+57.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
SI-BONE Inc
SIBN
9
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 8.10, which is higher than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 16.34 and the support level at 14.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.40
Change
1.7

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.056
Buy
RSI(14)
57.387
Neutral
STOCH(KDJ)(9,3,3)
65.918
Buy
ATR(14)
0.627
Low Volatility
CCI(14)
69.708
Neutral
Williams %R
15.825
Overbought
TRIX(12,20)
0.091
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
15.344
Buy
MA10
15.341
Buy
MA20
15.287
Buy
MA50
15.226
Buy
MA100
16.100
Sell
MA200
16.243
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 96.04%, representing a quarter-over-quarter decrease of 3.61%. The largest institutional shareholder is The Vanguard, holding a total of 2.44M shares, representing 5.66% of shares outstanding, with 1.18% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
2.97M
-7.98%
Brown Advisory
2.91M
-8.61%
OrbiMed Advisors, LLC
2.58M
-25.09%
The Vanguard Group, Inc.
Star Investors
2.44M
+0.18%
American Century Investment Management, Inc.
2.32M
-12.33%
Champlain Investment Partners, LLC
2.14M
-17.55%
First Light Asset Management, LLC
1.75M
+8.60%
Silvercrest Asset Management Group LLC
1.48M
-8.79%
Granahan Investment Management, LLC
1.26M
-11.75%
State Street Investment Management (US)
1.03M
-4.91%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 5.86, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 0.78. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.86
Change
0
Beta vs S&P 500 index
0.77
VaR
+4.77%
240-Day Maximum Drawdown
+29.23%
240-Day Volatility
+53.04%

Return

Best Daily Return
60 days
+5.80%
120 days
+7.93%
5 years
+18.97%
Worst Daily Return
60 days
-5.98%
120 days
-10.61%
5 years
-24.33%
Sharpe Ratio
60 days
+0.23
120 days
-0.92
5 years
+0.02

Risk Assessment

Maximum Drawdown
240 days
+29.23%
3 years
+58.72%
5 years
+68.77%
Return-to-Drawdown Ratio
240 days
+0.97
3 years
+0.19
5 years
-0.13
Skewness
240 days
+1.24
3 years
+0.58
5 years
-0.02

Volatility

Realised Volatility
240 days
+53.04%
5 years
+57.65%
Standardised True Range
240 days
+4.50%
5 years
+6.07%
Downside Risk-Adjusted Return
120 days
-122.80%
240 days
-122.80%
Maximum Daily Upside Volatility
60 days
+23.01%
Maximum Daily Downside Volatility
60 days
+24.10%

Liquidity

Average Turnover Rate
60 days
+1.05%
120 days
+1.03%
5 years
--
Turnover Deviation
20 days
+19.87%
60 days
+9.03%
120 days
+7.25%

Peer Comparison

Healthcare Equipment & Supplies
SI-BONE Inc
SI-BONE Inc
SIBN
7.89 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI